ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 704.54 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 168.11K shares.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 536.43K shares, a 34.11% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 0.00 shares.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 704.54K shares, a 70.36% decline from fiscal 2024.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.38M shares, a 35.82% increase from fiscal 2023.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.75M shares, a 9.20% decline from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.93M shares, a 43.89% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 168.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 704.54K shares derived: sum of 2 quarters · filed 2026-03-10 | 704.54K shares derived: sum of 3 quarters · filed 2026-03-10 | 704.54K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 536.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 536.43K shares derived: sum of 2 quarters · filed 2025-11-12 | 536.43K shares 10-Q · filed 2025-11-12 | 536.43K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2025-07-24 | 0.00 shares 10-Q · filed 2025-07-24 | 0.00 shares derived: sum of 3 quarters · filed 2025-07-24 | 400.00K shares derived: sum of 4 quarters · filed 2025-07-24 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 0.00 shares derived: sum of 2 quarters · filed 2025-05-08 | 400.00K shares derived: sum of 3 quarters · filed 2025-05-08 | |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 400.00K shares derived: sum of 2 quarters · filed 2025-03-06 | 2.38M shares 10-K · filed 2025-03-06 | |
| 2024-09-30 | 400.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 2.38M shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 1.98M shares 10-Q · filed 2024-08-08 | |||
| 2023-12-31 | 1.75M shares 10-K · filed 2024-03-12 | |||
| 2022-12-31 | 46.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | 423.18K shares derived: sum of 2 quarters · filed 2023-03-14 | 1.05M shares derived: sum of 3 quarters · filed 2023-03-14 | 1.93M shares 10-K · filed 2023-03-14 |
| 2022-09-30 | 376.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 1.00M shares derived: sum of 2 quarters · filed 2022-11-07 | 1.88M shares 10-Q · filed 2022-11-07 | 2.32M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 627.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.50M shares 10-Q · filed 2022-08-11 | 1.94M shares derived: sum of 3 quarters · filed 2022-08-11 | 2.37M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 876.52K shares 10-Q · filed 2022-05-12 | 1.31M shares derived: sum of 2 quarters · filed 2022-05-12 | 1.74M shares derived: sum of 3 quarters · filed 2022-05-12 | 1.94M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 437.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 866.17K shares derived: sum of 2 quarters · filed 2022-03-17 | 1.06M shares derived: sum of 3 quarters · filed 2022-03-17 | 3.44M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 428.71K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 624.24K shares derived: sum of 2 quarters · filed 2021-11-10 | 3.00M shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 195.54K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 2.57M shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 2.37M shares 10-Q · filed 2021-05-13 | |||
| 2020-03-31 | 0.00 shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |